- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET April 24, 2024 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnol

April 18, 2024 -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that it has entered into a $55.0 million non-dilutive term loan agreement with CRG Servicing LLC, an affiliate of CRG

April 17th, 2024. Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of £19M ($24.5M) with the addition of Sound Bioventures as a new investor. Sound Bioventures joins a strong international syndicate of existing investors participating in the round that includes M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises and the University of Oxford. The pr

April 15, 2024 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement with Syntone Ventures, LLC, an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the Company’s common stock and accompan

£3.7 million seed financing supported by consortium of new and existing investors will fund continued preclinical development of therapeutic pipeline programmes. 18 March 2024: SENISCA, an award-winning biotechnology company developing RNA-based senotherapeutics to treat age-related disease, today announces it has raised an additional £3.7 million in funding. This comprises significant backing from SENISCA’s strong investor base, including Emerging Longevity Ventures, QantX, the R42 Group, Trend

March 11, 2024 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce, in partnership with TransBIOTech (Quebec), being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering Council of Canada in collabor

- First participant dosed in Phase 1/2 PROSPER trial of FMC-376 in KRASG12C Cancers - FMC-376 is a first-in-class direct dual inhibitor of ON+OFF KRASG12C - FMC-376 has the potential to transform patient outcomes with its ability to overcome both innate and acquired resistance mechanisms and brain metastases Feb. 22, 2024 -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-cau

Jan. 29, 2024 -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced achievement of operational requirements in NANORAY-312, an ongoing pivotal Phase 3 study evaluating potential first-in-class radioenhancer NBTXR3 for elderly patients with head and neck cancer, resulting in a $20M milestone payment from strategic partner Janssen

Financing was led by New Enterprise Associates (NEA) and closed with additional new investor Atlas Venture and continued investment by GV and F-Prime Capital Significant investment by top-tier syndicate endorses Comanche’s innovative science, notable clinical progress, and experienced team of siRNA and maternal health experts tackling the extraordinary unmet needs in preeclampsia Comanche’s lead siRNA drug candidate, CBP-4888, targets an underlying cause of preeclampsia: over-production of the p

The in-kind Target ALS Foundational grant will support the development of first-in-class condensate-modifying drugs (c-mods) targeting the TDP-43 condensatopathy in ALS animal model Jan. 16, 2024 -- Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concep